Summit Creek Advisors LLC Reduces Stock Holdings in Medpace Holdings, Inc. $MEDP

Summit Creek Advisors LLC reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 46.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,288 shares of the company’s stock after selling 15,934 shares during the period. Summit Creek Advisors LLC’s holdings in Medpace were worth $10,271,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Optiver Holding B.V. purchased a new position in Medpace in the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace in the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new position in Medpace in the fourth quarter valued at approximately $30,000. Quarry LP purchased a new position in Medpace in the third quarter valued at approximately $35,000. Finally, Root Financial Partners LLC purchased a new position in Medpace in the third quarter valued at approximately $38,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 20.50% of the stock is currently owned by company insiders.

Medpace Price Performance

NASDAQ:MEDP opened at $421.87 on Thursday. The firm’s fifty day moving average price is $460.55 and its 200 day moving average price is $521.15. Medpace Holdings, Inc. has a 1-year low of $287.17 and a 1-year high of $628.92. The firm has a market cap of $12.05 billion, a price-to-earnings ratio of 26.52, a price-to-earnings-growth ratio of 2.13 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period last year, the firm posted $3.67 EPS. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, The Gross Law Firm, and Bleichmar Fonti & Auld, announced or promoted class action claims against Medpace Holdings, Inc. (MEDP), keeping legal overhang in focus for shareholders. Article Title
• Negative Sentiment: The lawsuits allege investor harm tied to disclosures about cancellation rates and other operating metrics, which could raise litigation costs and uncertainty around management credibility. Article Title
• Negative Sentiment: The repeated reminders about June 2026 filing deadlines suggest the legal situation is still active and could remain a drag on sentiment in the near term. Article Title
• Neutral Sentiment: Separately, Medpace shareholders approved governance changes enhancing voting rights at the company’s annual meeting, but this appears less immediately impactful than the litigation headlines. Article Title

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent analyst reports. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Truist Financial lowered their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research report on Friday, February 13th. Leerink Partners lowered their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.